MX361741B - Tratamientos médicos a base de anamorelina. - Google Patents

Tratamientos médicos a base de anamorelina.

Info

Publication number
MX361741B
MX361741B MX2017002825A MX2017002825A MX361741B MX 361741 B MX361741 B MX 361741B MX 2017002825 A MX2017002825 A MX 2017002825A MX 2017002825 A MX2017002825 A MX 2017002825A MX 361741 B MX361741 B MX 361741B
Authority
MX
Mexico
Prior art keywords
anamorelin
medical treatments
cancer
therapeutically effective
treatments based
Prior art date
Application number
MX2017002825A
Other languages
English (en)
Spanish (es)
Other versions
MX2017002825A (es
Inventor
Lu Ming
Mann William
Friend John
Polvino William
Allen Suzan
Duus Elizabeth
Giorgino Ruben
Baroni Enrico
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55436476&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX361741(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of MX2017002825A publication Critical patent/MX2017002825A/es
Publication of MX361741B publication Critical patent/MX361741B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
MX2017002825A 2014-09-04 2015-08-28 Tratamientos médicos a base de anamorelina. MX361741B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462045976P 2014-09-04 2014-09-04
PCT/US2015/047435 WO2016036598A1 (en) 2014-09-04 2015-08-28 Medical treatments based on anamorelin

Publications (2)

Publication Number Publication Date
MX2017002825A MX2017002825A (es) 2017-09-28
MX361741B true MX361741B (es) 2018-12-14

Family

ID=55436476

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017002825A MX361741B (es) 2014-09-04 2015-08-28 Tratamientos médicos a base de anamorelina.

Country Status (44)

Country Link
US (5) US9675600B2 (OSRAM)
EP (2) EP3188599B1 (OSRAM)
JP (3) JP6356907B2 (OSRAM)
KR (3) KR102307275B1 (OSRAM)
CN (5) CN109172575A (OSRAM)
AP (1) AP2017009772A0 (OSRAM)
AR (1) AR103118A1 (OSRAM)
AU (1) AU2015312231B2 (OSRAM)
BR (1) BR112017003552A2 (OSRAM)
CA (1) CA2959158A1 (OSRAM)
CL (1) CL2017000494A1 (OSRAM)
CO (1) CO2017003263A2 (OSRAM)
CR (1) CR20170121A (OSRAM)
CY (1) CY1122746T1 (OSRAM)
DK (1) DK3188599T3 (OSRAM)
DO (1) DOP2017000055A (OSRAM)
EA (1) EA035578B1 (OSRAM)
EC (1) ECSP17019893A (OSRAM)
ES (1) ES2761777T3 (OSRAM)
GE (2) GEP20186939B (OSRAM)
HR (1) HRP20192345T1 (OSRAM)
HU (1) HUE046894T2 (OSRAM)
IL (1) IL250692B (OSRAM)
JO (1) JO3541B1 (OSRAM)
LT (1) LT3188599T (OSRAM)
MA (1) MA40607B1 (OSRAM)
MD (1) MD4710C1 (OSRAM)
ME (1) ME03597B (OSRAM)
MX (1) MX361741B (OSRAM)
MY (1) MY187167A (OSRAM)
NI (1) NI201700024A (OSRAM)
PE (1) PE20171109A1 (OSRAM)
PH (1) PH12017500392B1 (OSRAM)
PL (1) PL3188599T3 (OSRAM)
PT (1) PT3188599T (OSRAM)
RS (1) RS59751B1 (OSRAM)
SG (1) SG11201701567UA (OSRAM)
SI (1) SI3188599T1 (OSRAM)
SV (1) SV2017005400A (OSRAM)
TN (1) TN2017000040A1 (OSRAM)
TW (1) TWI639429B (OSRAM)
UA (1) UA120765C2 (OSRAM)
UY (1) UY36286A (OSRAM)
WO (1) WO2016036598A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014159609A1 (en) 2013-03-14 2014-10-02 Allergen Research Corporation Peanut formulations and uses thereof
GEP20186939B (en) 2014-09-04 2018-12-25 Healthcare Sa Helsinn Medical treatments based on anamorelin
EP3836801A4 (en) 2018-08-16 2022-05-18 Société des Produits Nestlé S.A. Peanut oral immunotherapy with maintenance dose
WO2020132341A1 (en) 2018-12-20 2020-06-25 Aimmune Therapeutics, Inc. Peanut oral immunotherapy dosing schedule for missed doses
CA3137295A1 (en) 2019-05-10 2020-11-19 Aimmune Therapeutics, Inc. Methods for improving the quality of life of a patient with a peanut allergy
BR112022002767A2 (pt) 2019-08-30 2022-05-10 Helsinn Healthcare Sa Métodos de fabricação de um comprimido de cloridrato de anamorelina, comprimidos e método para melhorar um ou mais sintomas de caquexia de câncer
WO2021079978A1 (ja) * 2019-10-24 2021-04-29 東レ株式会社 悪液質の治療剤又は予防剤
JP2024534464A (ja) * 2021-09-17 2024-09-20 小野薬品工業株式会社 食欲不振／悪液質患者における患者報告アウトカムに関する臨床的に意味のある改善を判定し、提供する方法
WO2025004650A1 (ja) * 2023-06-28 2025-01-02 日清オイリオグループ株式会社 中高年者の疲労感を軽減するための剤及び組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303620B1 (en) 1998-05-11 2001-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
ECSP993020A (es) 1999-06-16 1999-08-12 Terapia de combinacion para la fragilidad musculoesqueletica
ECSP993021A (es) 1999-06-16 1999-08-12 Combinaciones terapeuticas para la fragilidad musculoesqueletica
US20010020012A1 (en) 2000-02-01 2001-09-06 Andersen Maibritt Bansholm Use of compounds for the regulation of food intake
CN1863550A (zh) * 2003-08-06 2006-11-15 加斯特罗泰克药物公司 促分泌素样生长素释放肽在癌症恶病质中以及在刺激食欲方面的应用
WO2005014032A2 (en) 2003-08-06 2005-02-17 Gastrotech Pharma A/S Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite
KR20070010151A (ko) 2004-03-30 2007-01-22 사파이어 세라퓨틱스, 인크. 성장 호르몬 분비촉진제를 이용하여 ｃ-반응성 단백질을감소시키는 방법
EP2298760B1 (en) * 2004-06-29 2015-08-05 Helsinn Healthcare S.A. Crystal forms of (3R)-1-(2-methylalanyl-D-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide
MX2009008561A (es) * 2007-02-13 2010-01-15 Helsinn Therapeutics Us Inc Metodo para tratar trastornos proliferativos celulares utilizando secretagogos.
TWI429436B (zh) * 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
JO3353B1 (ar) * 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
CN104470524A (zh) * 2012-05-25 2015-03-25 拉夸里亚创药株式会社 用于治疗胃酸缺乏症的生长激素释放肽受体激动剂
GEP20186939B (en) 2014-09-04 2018-12-25 Healthcare Sa Helsinn Medical treatments based on anamorelin

Also Published As

Publication number Publication date
JP2018154655A (ja) 2018-10-04
EP3188599A4 (en) 2017-10-11
MD4710C1 (ro) 2021-04-30
JP7044918B2 (ja) 2022-03-30
TW201613587A (en) 2016-04-16
US9675600B2 (en) 2017-06-13
DK3188599T3 (da) 2019-11-25
EA201790352A1 (ru) 2017-07-31
US20190175574A1 (en) 2019-06-13
EP3188599B1 (en) 2019-10-02
US20210093627A1 (en) 2021-04-01
MD4710B1 (ro) 2020-09-30
MX2017002825A (es) 2017-09-28
PH12017500392A1 (en) 2017-07-17
IL250692B (en) 2019-05-30
RS59751B1 (sr) 2020-02-28
PT3188599T (pt) 2020-01-15
BR112017003552A2 (pt) 2017-12-05
NI201700024A (es) 2017-07-18
UY36286A (es) 2016-02-29
CN107205389A (zh) 2017-09-26
MA40607B1 (fr) 2019-11-29
JP2021080281A (ja) 2021-05-27
US10278964B2 (en) 2019-05-07
ECSP17019893A (es) 2017-05-31
NZ729673A (en) 2023-09-29
CA2959158A1 (en) 2016-03-10
PH12017500392B1 (en) 2018-08-31
SI3188599T1 (sl) 2020-02-28
AU2015312231A1 (en) 2017-03-23
CN113577073A (zh) 2021-11-02
ME03597B (me) 2020-07-20
WO2016036598A1 (en) 2016-03-10
US20240024303A1 (en) 2024-01-25
GEAP201814459A (en) 2018-09-10
AR103118A1 (es) 2017-04-19
TN2017000040A1 (en) 2018-07-04
KR102234319B1 (ko) 2021-04-01
IL250692A0 (en) 2017-04-30
PL3188599T3 (pl) 2020-06-01
SV2017005400A (es) 2017-04-20
PE20171109A1 (es) 2017-08-07
HUE046894T2 (hu) 2020-04-28
KR101881264B1 (ko) 2018-07-23
MD20170025A2 (ro) 2017-07-31
UA120765C2 (uk) 2020-02-10
KR20180085047A (ko) 2018-07-25
EP3188599A1 (en) 2017-07-12
CN109172575A (zh) 2019-01-11
AU2015312231B2 (en) 2017-10-19
ES2761777T3 (es) 2020-05-21
CN113577074A (zh) 2021-11-02
CO2017003263A2 (es) 2017-07-28
DOP2017000055A (es) 2017-08-15
US10894041B2 (en) 2021-01-19
US20160067236A1 (en) 2016-03-10
KR102307275B1 (ko) 2021-09-30
KR20210035923A (ko) 2021-04-01
HRP20192345T1 (hr) 2020-03-20
JP2017526695A (ja) 2017-09-14
CY1122746T1 (el) 2021-03-12
CL2017000494A1 (es) 2017-09-15
CR20170121A (es) 2017-07-17
JO3541B1 (ar) 2020-07-05
KR20170047372A (ko) 2017-05-04
JP6356907B2 (ja) 2018-07-11
US11723902B2 (en) 2023-08-15
CN107375285A (zh) 2017-11-24
MY187167A (en) 2021-09-07
LT3188599T (lt) 2019-12-10
AP2017009772A0 (en) 2017-02-28
EA035578B1 (ru) 2020-07-09
GEP20186939B (en) 2018-12-25
SG11201701567UA (en) 2017-03-30
US20170296526A1 (en) 2017-10-19
EP3590338A2 (en) 2020-01-08
JP6923486B2 (ja) 2021-08-18
EP3590338A3 (en) 2020-03-18
TWI639429B (zh) 2018-11-01

Similar Documents

Publication Publication Date Title
MX361741B (es) Tratamientos médicos a base de anamorelina.
MX2021002322A (es) Nuevos metodos.
CL2018001677A1 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
MX2017005875A (es) Metodos para tratar enfermedades oculares.
TWD196868S (zh) 超音波治療手持件
EA201791199A1 (ru) Способ лечения болезни альцгеймера
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
AU2018326364A1 (en) Methods of enhancing and/or stabilizing cardiac function in patients with Fabry disease
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
EA200970345A1 (ru) Лечение гипербилирубинемии новорожденных с использованием низких дозировок станнсопорфина
MX390722B (es) Tratamiento de resistencia a diureticos.
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
EA202090242A1 (ru) Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
MX2025002392A (es) Formulaciones de dantroleno y metodos de uso de dichas formulaciones
UA113183C2 (xx) Спосіб лікування адикції
GT201700041A (es) Tratamientos médicos a base de anamorelina
EA201890019A1 (ru) Способ профилактики недостаточности трансплантата у реципиента
AR102494A1 (es) Métodos para tratar enfermedades oculares
Fabiny Ask the doctor. I recently took antibiotics to treat an oral infection and as a result developed a vaginal yeast infection. Can I treat it myself, and what are the most effective options?
RU2015109209A (ru) Способ количественной оценки зубочелюстно-лицевых аномалий
EA201991866A1 (ru) Комбинированная терапия
EA201692163A1 (ru) Лекарственное средство для лечения пациентов с тиннитусом
UA116484U (uk) Cпосіб лікування артеріальної гіпертензії з метаболічним синдромом
UA115063U (xx) Спосіб лікування собак із больовим синдромом при панкреатиті

Legal Events

Date Code Title Description
FG Grant or registration